- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Arcellx CMO sells over $239k in company stock | 1 | Investing.com | ||
| Mi | Arcellx executive sells over $1.8 million in company stock | 1 | Investing.com | ||
| 09.08. | Assessing Arcellx: Insights From 7 Financial Analysts | 1 | Benzinga.com | ||
| 09.08. | Arcellx GAAP EPS of -$0.51, revenue of $27.38M | 1 | Seeking Alpha | ||
| 08.08. | Arcellx, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Arcellx Provides Second Quarter 2024 Financial Results and Business Updates | 58 | Business Wire | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| 02.08. | Here's Why Arcellx (ACLX) Slipped in Q2 | 1 | Insider Monkey | ||
| 22.07. | Decoding 8 Analyst Evaluations For Arcellx | 1 | Benzinga.com | ||
| 18.06. | The Latest Analyst Ratings For Arcellx | 2 | Benzinga.com | ||
| 31.05. | Expert Ratings For Arcellx | 3 | Benzinga.com | ||
| 14.05. | Analyst Expectations For Arcellx's Future | 2 | Benzinga.com | ||
| 10.05. | Arcellx GAAP EPS of -$0.14, revenue of $39.3M | 1 | Seeking Alpha | ||
| 09.05. | Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset | 19 | Seeking Alpha | ||
| 09.05. | Arcellx, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Arcellx Provides First Quarter 2024 Financial Results | 95 | Business Wire | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| 23.04. | Should You Be Bullish on Arcellx (ACLX)? | 3 | Insider Monkey | ||
| 25.03. | Arcellx director sells over $35 million in company stock | 1 | Investing.com | ||
| 19.03. | Arcellx CFO sells over $470k in company stock | 1 | Investing.com | ||
| 18.03. | Arcellx director Ware sells over $630k in company stock | 1 | Investing.com |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,600 | -4,15 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,351 | -1,96 % | Defence Therapeutics Inc.: Defence Appoints New Interim Chief Executive Officer | Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed... ► Artikel lesen | |
| GINKGO BIOWORKS | 5,460 | +7,27 % | Ginkgo Bioworks: Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement | BOSTON, Sept. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,915 | -4,13 % | Recursion Pharmaceuticals, Inc.: Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,280 | -3,72 % | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results | U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,750 | 0,00 % | ONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer | ||
| ASSERTIO | 1,265 | -0,39 % | Assertio Holdings, Inc.: Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024 | ||
| ARCTURUS THERAPEUTICS | 18,690 | -0,69 % | Canaccord maintains Buy rating on Arcturus stock with consistent price target | ||
| SIGA TECHNOLOGIES | 7,710 | -3,26 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,250 | -3,04 % | Adma biologics executive trades shares worth over $400,000 | ||
| VIR BIOTECHNOLOGY | 7,760 | +1,44 % | Vir Biotechnology stock hits 52-week low at $7.61 | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,590 | +1,08 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,340 | -3,49 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy offers adults and children (=30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU
European Commission decision... ► Artikel lesen | |
| ARVINAS | 24,420 | -2,12 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen |
ARCELLX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,18 % bei einem Aktienkurs von 71,20 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCELLX INC finden Sie auf Wallstreet Online.
